BioStem Technologies CFO converts awards to 2,699 shares

Available on EDGAR 11/13/2026 - 04:31 PM EST Accepted by SEC EDGAR 11/13/2026 - 04:30 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

BioStem Technologies, Inc. (BSEM) Chief Financial Officer Brandon Poe reported converting 2,699 restricted stock units into 2,699 common shares on November 11, 2026. His reported direct common-stock holdings after the transaction were 60,763 shares; that figure includes an adjustment for two shares incorrectly excluded in prior reports.

The report also lists direct options covering 38,814 common shares at $6.48, expiring August 19, 2035, and options covering 117,401 common shares at $5.50, expiring February 11, 2036. It lists 6,773 and 96,909 restricted stock units. The converted units had 33% vested on August 11, 2026, with the remaining units vesting in equal quarterly installments over the subsequent two years.

Insider Trade Summary

2,699 shares exercised/converted

Exercise 2 txns

Insider POE BRANDON

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units F4, F6	2,699	$0.00	$0.00
Exercise	Common Stock F1	2,699	$0.00	$0.00
Holding	Options (Right to Buy) F2	--	--	--
Holding	Options (Right to Buy) F3	--	--	--
Holding	Restricted Stock Units F4, F5, F1	--	--	--
Holding	Restricted Stock Units F4, F7	--	--	--

Holdings After Transaction: Restricted Stock Units — 122,574 units, with 103,682 underlying shares of Common Stock (Direct); Common Stock — 60,763 shares (Direct); Options (Right to Buy) — 156,215 options (Direct)

Holdings Before and After: Restricted Stock Units, 125,273 to 122,574 units (Direct); Common Stock, 58,064 to 60,763 shares (Direct)

Footnotes (7)

1. F1. Reflects an adjustment to total holdings to include two shares incorrectly excluded in prior reports.
2. F2. These options vest according to the following schedule: 33% vested on August 11, 2026, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
3. F3. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
4. F4. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
5. F5. These restricted stock units vest in equal quarterly installments over three year from the grant date (September 15, 2024).
6. F6. These restricted stock units vest according to the following schedule: 33% vested on August 11, 2026, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
7. F7. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.

Key Figures

Common shares acquired upon conversion: 2,699 shares Direct common shares after transaction: 60,763 shares Options covering common shares: 38,814 shares at $6.48 +3 more

6 metrics

Common shares acquired upon conversion 2,699 shares November 11, 2026

Direct common shares after transaction 60,763 shares Reported after the November 11, 2026 transaction; includes an adjustment for two shares incorrectly excluded in prior reports

Options covering common shares 38,814 shares at $6.48 Expiration date: August 19, 2035

Options covering common shares 117,401 shares at $5.50 Expiration date: February 11, 2036

Restricted stock units 6,773 units Vest in equal quarterly installments over three years from September 15, 2024

Restricted stock units 96,909 units 33% will vest on February 11, 2027; remaining units vest in equal quarterly installments over the subsequent two years

Key Terms

Restricted Stock Units, contingent right, equal quarterly installments, Options (Right to Buy)

4 terms

Restricted Stock Units technical

"Each restricted stock unit represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right technical

"a contingent right to receive one share of the issuer's common stock"

equal quarterly installments technical

"remaining options vesting in equal quarterly installments over the subsequent two year period"

Options (Right to Buy) technical

"Options (Right to Buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BSEM shares did CFO Brandon Poe receive?

Brandon Poe, BioStem Technologies' chief financial officer, converted 2,699 restricted stock units into 2,699 common shares on November 11, 2026. His reported common-stock holdings after the transaction were 60,763 shares, including an adjustment for two shares incorrectly excluded in prior reports.

What is the vesting schedule for Brandon Poe's BSEM restricted stock units?

The 2,699 units had 33% vested on August 11, 2026, with the remaining units vesting in equal quarterly installments over the subsequent two years. The 6,773 units vest in equal quarterly installments over three years from September 15, 2024. For the 96,909 units, 33% will vest on February 11, 2027, with the remainder vesting in equal quarterly installments over the following two years.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

POE BRANDON

(Last) (First) (Middle)

C/O BIOSTEM TECHNOLOGIES, INC.

2836 CENTER PORT CIRCLE

(Street)

POMPANO BEACH FLORIDA 33064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioStem Technologies, Inc. [ BSEM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/11/2026		M		2,699	A	$0.00	60,763(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (Right to Buy)	$6.48							(2)	08/19/2035	Common Stock	38,814		38,814	D
Options (Right to Buy)	$5.5							(3)	02/11/2036	Common Stock	117,401		117,401	D
Restricted Stock Units	(4)							(5)	(5)	Common Stock	6,773		6,773(1)	D
Restricted Stock Units	(4)	11/11/2026		M			2,699	(6)	(6)	Common Stock	2,699	$0.00	18,892	D
Restricted Stock Units	(4)							(7)	(7)	Common Stock	96,909		96,909	D

Explanation of Responses:

1. Reflects an adjustment to total holdings to include two shares incorrectly excluded in prior reports.

2. These options vest according to the following schedule: 33% vested on August 11, 2026, with the remaining options vesting in equal quarterly installments over the subsequent two year period.

3. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.

4. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

5. These restricted stock units vest in equal quarterly installments over three year from the grant date (September 15, 2024).

6. These restricted stock units vest according to the following schedule: 33% vested on August 11, 2026, with the remaining units vesting in equal quarterly installments over the subsequent two year period.

7. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.

	/s/ Katherine Gorrell, Attorney-in-Fact	11/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)